15 completed, 2 unknown, 1 terminated, 1 withdrawn. 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 15, Unknown 2, Terminated 1, Withdrawn 1 |
Follow Tinea Pedis: new trials by email Literature Review of Tinea Pedis trials Research Report on Tinea Pedis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Therapeutic Equivalence Study of Ketoconazole Cream 2% Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.) - Tinea Pedis | Phase 3 | Completed | Douglas Pharmaceuticals America Ltd | 682 | 2019-12-11 | 2020-08-06 |
| Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo - Tinea Pedis | Phase 3 | Completed | Encube Ethicals Pvt. Ltd. | 831 | 2018-08-23 | 2019-06-27 |
| Non-inferiority Trial of Dapaconazole Versus Ketoconazole Dapaconazole, Ketoconazole - Tinea Pedis | Phase 3 | Completed | Biolab Sanus Farmaceutica | 360 | 2017-11-01 | 2020-07-27 |
| Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis Dapaconazole, Ketoconazole - Tinea Pedis | Phase 3 | Withdrawn | Biolab Sanus Farmaceutica | 2016-06-01 | 2017-02-01 | |
| Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Econazole Nitrate Cream, 1%, Placebo - Tinea Pedis | Phase 3 | Completed | Mylan Inc. | 876 | 2016-03-15 | 2022-03-07 |
| BE Study of Naftifine HCL Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%) - Tinea Pedis | Phase 3 | Completed | Genzum Life Sciences | 693 | 2015-03-01 | 2017-05-11 |
| Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Clotrimazole - Fungal Infections, Tinea Pedis | Phase 3 | Unknown | Laboratório Teuto Brasileiro S/A | 90 | 2012-04-01 | 2012-04-12 |
| Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Terbinafine, Terbinafine Placebo - Tinea Pedis | Phase 3 | Completed | Novartis | 290 | 2011-08-01 | 2013-12-27 |
| Topical Antifungal Treatment for Tinea Pedis 33525, Placebo - Tinea Pedis | Phase 3 | Completed | Medicis Global Service Corporation | 321 | 2011-07-01 | 2013-08-28 |
| Topical Antifungal Treatment for Tinea Pedis 33525, Placebo - Tinea Pedis | Phase 3 | Completed | Medicis Global Service Corporation | 322 | 2011-07-01 | 2013-08-28 |
| Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1% - Tinea Pedis, Athlete's Foot | Phase 3 | Completed | AmDerma | 336 | 2011-06-01 | 2012-09-28 |
| Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Product 33525 - Tinea Pedis, Tinea Cruris | Phase 3 | Completed | Tinea Pharmaceuticals | 604 | 2011-05-01 | 2013-01-23 |
| Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Econazole Nitrate Foam 1%, Vehicle Foam - Tinea Pedis, Athlete's Foot | Phase 3 | Completed | AmDerma | 264 | 2011-05-01 | 2013-01-09 |
| Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis NAFT-600 (naftin 2 % gel), Placebo - Tinea Pedis | Phase 3 | Completed | Merz North America, Inc. | 860 | 2011-02-01 | 2013-09-26 |
| Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis NAFT-600 ( naftin 2 % gel ), Placebo - Tinea Pedis | Phase 3 | Completed | Merz North America, Inc. | 855 | 2011-02-01 | 2013-09-26 |
| Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Sertaconazole nitrate cream 2% - Tinea Pedis, Athlete's Foot | Phase 3 | Unknown | Jamaica Hospital Medical Center | 30 | 2009-03-01 | 2009-08-06 |
| Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis NAFT-500, Placebo 2-weeks, Naftin 1% - Tinea Pedis, Athlete's Foot | Phase 3 | Completed | Merz North America, Inc. | 707 | 2008-08-01 | 2013-04-26 |
| An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot Placebo cream, Ketoconazole 2% cream (formulation F012) (Nizoral), Ketoconazole 2% cream (formulation F126) - Tinea Pedis | Phase 3 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 583 | 2007-07-01 | 2014-04-29 |
| Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis Ciclopirox Olamine Cream, Loprox Cream 0.77%, Placebo - Tinea Pedis | Phase 3 | Completed | Padagis LLC | 561 | 2003-12-01 | 2021-10-13 |
Mycoses (4) · Tinea (3) · Dermatomycoses (2) · Tinea Cruris (2) · Foot Diseases (1) · Pruritus (1) · Skin Diseases, Infectious (1) · Skin Manifestations (1)
Bacterial Infections and Mycoses (19) · Foot Dermatoses (19) · Infections (19) · Pathological Conditions, Signs and Symptoms (19) · Signs and Symptoms (19) · Skin Diseases (19) · Skin and Connective Tissue Diseases (19) · Foot Diseases (18) · Pruritus (18) · Skin Diseases, Infectious (18) · Skin Manifestations (18) · Dermatomycoses (17) · Tinea (16) · Mycoses (15) · Dermatitis (2)
Ketoconazole (3) · naftifine (3) · 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (2) · Gels (2) · Clotrimazole (1) · Terbinafine (1)
Merz North America, Inc. (3) · AmDerma (2) · Biolab Sanus Farmaceutica (2) · Medicis Global Service Corporation (2) · Douglas Pharmaceuticals America Ltd (1) · Encube Ethicals Pvt. Ltd. (1) · Genzum Life Sciences (1) · Jamaica Hospital Medical Center (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Laboratório Teuto Brasileiro S/A (1) · Mylan Inc. (1) · Novartis (1) · Padagis LLC (1) · Tinea Pharmaceuticals (1)
United States (12) · Belize (4) · Brazil (3) · Puerto Rico (3) · China (1) · Dominican Republic (1) · El Salvador (1) · Honduras (1) · Poland (1) · Saint Lucia (1) · United Kingdom (1)
Daniel Piacquadio, MD (2) · Lawrence Parish, MD (2) · Ron Staugaard (2) · Gilberto De Nucci, MD (1) · Gilberto De Nucci, PhD (1) · Jeffrey Weinberg, MD (1) · Lalatendu Panigrahi (1) · Lawrency Parrish, MD (1) · Zaidoon Al-Zubaidy (1)